These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 9690910

  • 1. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation.
    Aviram M, Rosenblat M, Bisgaier CL, Newton RS.
    Atherosclerosis; 1998 Jun; 138(2):271-80. PubMed ID: 9690910
    [Abstract] [Full Text] [Related]

  • 2. Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation.
    Sezer ED, Sozmen EY, Nart D, Onat T.
    Vasc Health Risk Manag; 2011 Jun; 7():333-43. PubMed ID: 21731885
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein.
    Jacob RF, Walter MF, Self-Medlin Y, Mason RP.
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):160-6. PubMed ID: 23575262
    [Abstract] [Full Text] [Related]

  • 6. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ.
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL.
    Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M.
    Atherosclerosis; 1997 Jan 03; 128(1):11-8. PubMed ID: 9051193
    [Abstract] [Full Text] [Related]

  • 9. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K, Pineda G, Newton RS, Fernandez ML.
    Biochem Pharmacol; 1999 Oct 01; 58(7):1209-19. PubMed ID: 10484079
    [Abstract] [Full Text] [Related]

  • 10. Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition.
    Vázquez M, Merlos M, Adzet T, Laguna JC.
    Br J Pharmacol; 1996 Mar 01; 117(6):1155-62. PubMed ID: 8882610
    [Abstract] [Full Text] [Related]

  • 11. Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients.
    Chen MF, Wang TD, Yeh HT, Hsu HC, Lee YT.
    Eur J Clin Invest; 2001 Aug 01; 31(8):707-13. PubMed ID: 11473572
    [Abstract] [Full Text] [Related]

  • 12. Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism.
    Mason RP, Jacob RF.
    Biochim Biophys Acta; 2015 Feb 01; 1848(2):502-9. PubMed ID: 25449996
    [Abstract] [Full Text] [Related]

  • 13. The antioxidative effects of the isoflavan glabridin on endogenous constituents of LDL during its oxidation.
    Belinky PA, Aviram M, Fuhrman B, Rosenblat M, Vaya J.
    Atherosclerosis; 1998 Mar 01; 137(1):49-61. PubMed ID: 9568736
    [Abstract] [Full Text] [Related]

  • 14. Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents.
    Mason RP, Sherratt SC, Jacob RF.
    J Cardiovasc Pharmacol; 2016 Jul 01; 68(1):33-40. PubMed ID: 26945158
    [Abstract] [Full Text] [Related]

  • 15. Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoprotein.
    Suzumura K, Tanaka K, Yasuhara M, Narita H.
    Biol Pharm Bull; 2000 Jul 01; 23(7):873-8. PubMed ID: 10919369
    [Abstract] [Full Text] [Related]

  • 16. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status.
    Orem C, Orem A, Uydu HA, Celik S, Erdöl C, Kural BV.
    Coron Artery Dis; 2002 Feb 01; 13(1):65-71. PubMed ID: 11917201
    [Abstract] [Full Text] [Related]

  • 17. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Krause BR, Newton RS.
    Atherosclerosis; 1995 Oct 01; 117(2):237-44. PubMed ID: 8801869
    [Abstract] [Full Text] [Related]

  • 18. Effects of fibrates on metabolism of statins in human hepatocytes.
    Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH.
    Drug Metab Dispos; 2002 Nov 01; 30(11):1280-7. PubMed ID: 12386136
    [Abstract] [Full Text] [Related]

  • 19. The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.
    Thallinger C, Urbauer E, Lackner E, Graselli U, Kostner K, Wolzt M, Joukhadar C.
    Int J Clin Pharmacol Ther; 2005 Dec 01; 43(12):551-7. PubMed ID: 16372516
    [Abstract] [Full Text] [Related]

  • 20. Lycopene synergistically inhibits LDL oxidation in combination with vitamin E, glabridin, rosmarinic acid, carnosic acid, or garlic.
    Fuhrman B, Volkova N, Rosenblat M, Aviram M.
    Antioxid Redox Signal; 2000 Dec 01; 2(3):491-506. PubMed ID: 11229363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.